Immunogenicity and Safety of AS03-adjuvanted H5N1 Influenza Vaccine in Children 6-35 Months of Age Results from a Phase 2, Randomized, Observer-blind, Multicenter, Dose-ranging Study
The Pediatric Infectious Disease Journal（2021）
Key words
AS03,influenza vaccine,children,dose finding
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined